X

Trial Profile

Effect of glatiramer acetate in patients with primary progressive Multiple Sclerosis

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 26 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glatiramer acetate (Primary)
Indications Multiple sclerosis
Focus Therapeutic Use
Acronyms PROMiSe

Most Recent Events

26 Sep 2022 Results assessing comparing clinical outcomes EDSS, timed 25-foot walk (T25FW), and nine-hole peg test, published in the Journal of Neurology.
28 Apr 2017 Results of reanalysis of PROMiSe trial dataset assessing characteristics and confirmed disability progression (CDP) rates of patients according to cerebrospinal fluid (CSF) status, presented at the 69th Annual Meeting of the American Academy of Neurology
05 Nov 2010 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com